Literature DB >> 19380467

The K5 capsule of Escherichia coli strain Nissle 1917 is important in mediating interactions with intestinal epithelial cells and chemokine induction.

Mohamed Hafez1, Kelly Hayes, Marie Goldrick, Geoff Warhurst, Richard Grencis, Ian S Roberts.   

Abstract

Escherichia coli strain Nissle 1917 has been widely used as a probiotic for the treatment of inflammatory bowel disorders and shown to have immunomodulatory effects. Nissle 1917 expresses a K5 capsule, the expression of which often is associated with extraintestinal and urinary tract isolates of E. coli. In this paper, we investigate the role of the K5 capsule in mediating interactions between Nissle 1917 and intestinal epithelial cells. We show that the loss of capsule significantly reduced the level of monocyte chemoattractant protein 1 (MCP-1), RANTES, macrophage inflammatory protein 2alpha (MIP-2alpha), MIP-2beta, interleukin-8, and gamma interferon-inducible protein 10 induction by Nissle 1917 in both Caco-2 cells and MCP-1 induction in ex vivo mouse small intestine. The complementation of the capsule-minus mutation confirmed that the effects on chemokine induction were capsule specific. The addition of purified K5, but not K1, capsular polysaccharide to the capsule-minus Nissle 1917 at least in part restored chemokine induction to wild-type levels. The purified K5 capsular polysaccharide alone was unable to stimulate chemokine production, indicating that the K5 polysaccharide was acting to mediate interactions between Nissle 1917 and intestinal epithelial cells. The induction of chemokine by Nissle 1917 was generated predominantly by interaction with the basolateral surface of Caco-2 cells, suggesting that Nissle 1917 will be most effective in inducing chemokine expression where the epithelial barrier is disrupted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19380467      PMCID: PMC2708560          DOI: 10.1128/IAI.00040-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  52 in total

1.  The K1 capsule modulates trafficking of E. coli-containing vacuoles and enhances intracellular bacterial survival in human brain microvascular endothelial cells.

Authors:  Kee Jun Kim; Simon Justin Elliott; Francescopaolo Di Cello; Monique Fabienne Stins; Kwang Sik Kim
Journal:  Cell Microbiol       Date:  2003-04       Impact factor: 3.715

2.  Cloning, expression, and purification of the K5 capsular polysaccharide lyase (KflA) from coliphage K5A: evidence for two distinct K5 lyase enzymes.

Authors:  B R Clarke; F Esumeh; I S Roberts
Journal:  J Bacteriol       Date:  2000-07       Impact factor: 3.490

3.  Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling.

Authors:  Andreas Sturm; Klaus Rilling; Daniel C Baumgart; Konstantinos Gargas; Tay Abou-Ghazalé; Bärbel Raupach; Jana Eckert; Ralf R Schumann; Corinne Enders; Ulrich Sonnenborn; Bertram Wiedenmann; Axel U Dignass
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

4.  Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.

Authors:  W Kruis; E Schütz; P Fric; B Fixa; G Judmaier; M Stolte
Journal:  Aliment Pharmacol Ther       Date:  1997-10       Impact factor: 8.171

5.  Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917.

Authors:  Lubomir Grozdanov; Carsten Raasch; Jürgen Schulze; Ulrich Sonnenborn; Gerhard Gottschalk; Jörg Hacker; Ulrich Dobrindt
Journal:  J Bacteriol       Date:  2004-08       Impact factor: 3.490

6.  Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.

Authors:  W Kruis; P Fric; J Pokrotnieks; M Lukás; B Fixa; M Kascák; M A Kamm; J Weismueller; C Beglinger; M Stolte; C Wolff; J Schulze
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

7.  Nonpathogenic Escherichia coli strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells.

Authors:  Nobuhiko Kamada; Kenichi Maeda; Nagamu Inoue; Tadakazu Hisamatsu; Susumu Okamoto; Kyong Su Hong; Takaya Yamada; Noriaki Watanabe; Kanji Tsuchimoto; Haruhiko Ogata; Toshifumi Hibi
Journal:  Infect Immun       Date:  2007-10-29       Impact factor: 3.441

8.  A microbial symbiosis factor prevents intestinal inflammatory disease.

Authors:  Sarkis K Mazmanian; June L Round; Dennis L Kasper
Journal:  Nature       Date:  2008-05-29       Impact factor: 49.962

Review 9.  The forward genetic dissection of afferent innate immunity.

Authors:  B Beutler; E M Y Moresco
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

10.  The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens.

Authors:  Artur Altenhoefer; Sibylle Oswald; Ulrich Sonnenborn; Corinne Enders; Juergen Schulze; Joerg Hacker; Tobias A Oelschlaeger
Journal:  FEMS Immunol Med Microbiol       Date:  2004-04-09
View more
  27 in total

Review 1.  Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa.

Authors:  Peter A Bron; Peter van Baarlen; Michiel Kleerebezem
Journal:  Nat Rev Microbiol       Date:  2011-11-21       Impact factor: 60.633

Review 2.  Modulating immunity as a therapy for bacterial infections.

Authors:  Robert E W Hancock; Anastasia Nijnik; Dana J Philpott
Journal:  Nat Rev Microbiol       Date:  2012-03-16       Impact factor: 60.633

Review 3.  Microbiota restoration: natural and supplemented recovery of human microbial communities.

Authors:  Gregor Reid; Jessica A Younes; Henny C Van der Mei; Gregory B Gloor; Rob Knight; Henk J Busscher
Journal:  Nat Rev Microbiol       Date:  2010-11-29       Impact factor: 60.633

4.  Cyclic AMP (cAMP) Receptor Protein-cAMP Complex Regulates Heparosan Production in Escherichia coli Strain Nissle 1917.

Authors:  Huihui Yan; Feifei Bao; Liping Zhao; Yanying Yu; Jiaqin Tang; Xianxuan Zhou
Journal:  Appl Environ Microbiol       Date:  2015-08-28       Impact factor: 4.792

Review 5.  Molecular dialogue between the human gut microbiota and the host: a Lactobacillus and Bifidobacterium perspective.

Authors:  Francesca Turroni; Marco Ventura; Ludovica F Buttó; Sabrina Duranti; Paul W O'Toole; Mary O'Connell Motherway; Douwe van Sinderen
Journal:  Cell Mol Life Sci       Date:  2013-03-21       Impact factor: 9.261

Review 6.  Probiotics: properties, examples, and specific applications.

Authors:  Judith Behnsen; Elisa Deriu; Martina Sassone-Corsi; Manuela Raffatellu
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

7.  A virulent parent with probiotic progeny: comparative genomics of Escherichia coli strains CFT073, Nissle 1917 and ABU 83972.

Authors:  Rebecca Munk Vejborg; Carsten Friis; Viktoria Hancock; Mark A Schembri; Per Klemm
Journal:  Mol Genet Genomics       Date:  2010-03-31       Impact factor: 3.291

8.  The K5 capsule of Escherichia coli strain Nissle 1917 is important in stimulating expression of Toll-like receptor 5, CD14, MyD88, and TRIF together with the induction of interleukin-8 expression via the mitogen-activated protein kinase pathway in epithelial cells.

Authors:  Mohamed Hafez; Kelly Hayes; Marie Goldrick; Richard K Grencis; Ian S Roberts
Journal:  Infect Immun       Date:  2010-02-09       Impact factor: 3.441

9.  Toward an Alternative Therapeutic Approach for Skin Infections: Antagonistic Activity of Lactobacilli Against Antibiotic-Resistant Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  Mohamed M Hafez; Ibrahim A Maghrabi; Noha M Zaki
Journal:  Probiotics Antimicrob Proteins       Date:  2013-09       Impact factor: 4.609

10.  Upregulation of Intestinal Mucin Expression by the Probiotic Bacterium E. coli Nissle 1917.

Authors:  Mohamed M Hafez
Journal:  Probiotics Antimicrob Proteins       Date:  2012-06       Impact factor: 4.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.